Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)

Panminerva Medica

Volumn 46, Issue 4, 2004, Pages 265-276

  Oberstein, S A J Lesnik ^a   Haan, J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNLAND HOSPITAL   (Netherlands)

Author keywords

CADASIL; NOTCH3; Stroke

Indexed keywords

CELL SURFACE RECEPTOR; NOTCH RECEPTOR; NOTCH3 PROTEIN, HUMAN; NOTCH3 PROTEIN, MOUSE; NOTCH4 PROTEIN, MOUSE; ONCOPROTEIN;

ADULT; AGED; ANIMAL; BRAIN ARTERY; CADASIL; CASE REPORT; DISEASE MODEL; DOMINANT GENE; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MOUSE; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PEDIGREE; REVIEW;

ADULT; AGED; ANIMALS; CADASIL; CEREBRAL ARTERIES; DISEASE MODELS, ANIMAL; FEMALE; GENES, DOMINANT; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MIDDLE AGED; MUTATION; PEDIGREE; PROTO-ONCOGENE PROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, NOTCH;

EID: 20044366609     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-10.
2. Dichgans M, Mayer M, Uttner I, Brüning R, Müller-Höcker J, Rungger G et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 1998;44:731-9.
3. Sourander P, Walinder J. Hereditary multi-infarct dementia. Acta Neuropathol 1977;39:247-54.
4. Stevens DL, Hewlett RH, Brownell B. Chronic familial vascular encephalopathy. Lancet 1977;1:1364-5.
5. Mas J-L, Dilouya A, Recondo de J. A familial disorder with subcortical ischemic strokes, dementia, and leukoencephalopathy. Neurology 1992;42:1015-9.
6. Salvi F, Michelucci R, Plasmati R, Parmeggiani L, Zonari P, Mascalchi M et al. Slowly progressive familial dementia with recurrent strokes and white matter hypodensities on CT scan. Ital J Neurol Sci 1992;13:135-40.
7. Gutierrez-Molina M, Caminero RA, Martinez GC, Arpa GJ, Morales BC, Amer G. Small arterial granular degeneration in familial Binswanger's syndrome. Acta Neuropathol (Berl) 1994;87:98-105.
8. Tournier-Lasserve E, Iba-Zizen M-T, Romero N, Bousser M-G. Autosomal dominant syndrome with strokelike episodes and leukoencephalopathy. Stroke 1991;22:1297-302.
9. Baudrimont M, Dubas F, Joutel A, Tournier-Lasserve E, Bousser M-G. Autosomal dominant leukoencephalopathy and subcortical ischemic stroke. Stroke 1993;24:122-5.
10. Chabriat H, Vahedi K, Iba-Zizen M-T, Joutel A, Nibbio A, Nagy TG et al. Clinical spectrum of CADASIL: a study of 7 families. Lancet 1995;346:934-9.
11. Ducros A, Nagy T, Alamowitch S, Nibbio A, Joutel A, Vahedi K et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, genetic homogeneity, and mapping of the locus within a 2-cM interval. Am J Hum Genet 1996;58:171-81.
12. Bousser M-G, Tournier-Lasserve E. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: from stroke to vessel wall physiology. J Neurol Neurosurg Psychiatry 2001;70:285-7.
13. Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain 2004;127:2533-9.
14. Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Mohr JP. The natural history of CADASIL. A pooled analysis of previously published cases. Stroke 1999;30:1230-3.
15. Lesnik Oberstein SAJ, van den Boom R, Middelkoop HAM, Ferrari MD, Knaap YM, van Houwelingen HC et al. Incipient CADASIL. Arch Neurol 2003;60:707-12.
16. Amberla K, Waljas M, Tuominen S, Almkvist O, Poyhonen M, Tuisku S et al. Insidious cognitive decline in CADASIL. Stroke 2004;35: 1598-602.
17. Ferrari MD. Migraine. Lancet 1998;351:1043-51.
18. Chabriat H, Tournier-Lasserve E, Vahedi K, Leys D, Joutel A, Nibbio A et al. Autosomal dominant migraine with MRI white-matter abnormalities mapping to the CADASIL locus. Neurology 1995;45: 1086-91.
19. Hutchinson M, O'Riordan J, Javed M, Quin E, Macerlaine D, Wilcox T et al. Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). Ann Neurol 1995;38:817-24.
20. Weller M, Dichgans J, Klockgether T. Acetozolamide-responsive migraine in CADASIL. Neurology 1998;50:1505.
21. Forteza AM, Brozman B, Rabinstein AA, Romano JG, Bradley WG. Acetazolamide for the treatment of migraine with aura in CADASIL. Neurology 2001;57:2144-5.
22. Lagas PA, Juvonen V. Schizophrenia in a patient with cerebral autosomally dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL disease). Nord J Psychiatry 2001;55: 41-2.
23. Lalith-Kumar SK, Mahr G. CADASIL presenting as bipolar disorder. Psychosomatics 1997;38:397-8.
24. Feuerhake F, Volk B, Ostertag B, Jungling D, Kassubek J, Orszagh M et al. Reversible coma with raised intracranial pressure: an unusual clinical manifestation of CADASIL. Acta Neuropathol (Berl) 2002;103: 188-92.
25. Schon F, Martin RJ, Prevett M, Clough C, Enevoldson TP, Markus HS. CADASIL coma: an underdiagnosed acute encephalopathy. J Neurol Neurosurg Psychiatry 2003;74:249-52.
26. Vahedi K, Tournier-Lasserve E, Chabriat H, Bousser M-G. An dditional monogenic disorder that masquerades as multiple sclerosis. Am J Med Genet 1996;65:357-8.
27. O'Riordan S, Nor AM, Hutchinson M. CADASIL imitating multiple sclerosis: the importance of MRI markers. Mult Scler 2002;8:430-2.
28. Singhal S, Bevan S, Barrick T, Rich P, Markus HS. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain 2004;127:2031-8.
29. Chabriat H, Levy C, Taillia H, Iba-Zizen M-T, Vahedi K, Joutel A et al. Patterns of MRI lesions in CADASIL. Neurology 1998;51:452-7.
30. Yousry TA, Seelos K, Mayer M, Burning R, Uttner I, Dichgans M et al. Characteristic MR lesion pattern and correlation of T1 and T2 lesion volume with neurologic and neuropsychological findings in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Am J Neuroradiol 1999;20:91-100.
31. Coulthard A, Blank SC, Bushby K, Kalaria RN, Burn DJ. Distribution of cranial MRI abnormalities in patients with symptomatic and subclinical CADASIL. Br J Radiol 2000;73:256-65.
32. O'Sullivan M, Jarosz JM, Martin RJ, Deasy N, Powell JF, Markus HS. MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology 2001;56:628-34.
33. Chabriat H, Mrissa R, Levy C, Vahedi K, Taillia H, Ibazizen MT et al. Brain stem MRI signal abnormalities in CADASIL. Stroke 1999;30:457-9.
34. van den Boom R, Lesnik Oberstein SAJ, Ferrari MD, Haan J, Buchem MA. CADASIL lesions on MRI in different age groups- third through sixth decades. Radiology 2003;229:683-90.
35. Ruchoux M-M, Maurage C-A. CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Neuropathol Exp Neurol 1997;56:947-64.
36. van den Boom R, Lesnik Oberstein SAJ, Bornebroek M, Ferrari MD, Haan J, van Buchem MA. Subcortical lacunar lesions, a novel MRI finding in CADASIL. Radiology 2002;224:791-6.
37. Lesnik Oberstein SAJ, van den Boom R, van Buchem MA, van Houwelingen HC, Bakker E, Vollebregt E et al. Cerebral microbleeds in CADASIL. Neurology 2001;57:1066-70.
38. Ruchoux M-M, Guerouaou D, Vandenhaute B, Pruvo J-P, Vermersch P, Leys D. Systemic vascular smooth muscle cell impairment in cerebral autosomal arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol 1995;89:500-12.
39. Lammie GA, Rakshi J, Rossor MN, Harding AE, Scaravilli F. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL): confirmation by cerebral biopsy in 2 cases. Clin Neuropathol 1995;14:201-6.
40. Ruchoux M-M, Chabriat H, Bousser M-G, Baudrimont M, Tournier-Lasserve E. Presence of ultrastructural arterial lesions in muscle and skin vessels of patients with CADASIL. Stroke 1994;25:2291-2.
41. Goebel HH, Meyermann R, Rosin R, Schlote W. Characteristic morphologic manifestation of CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, in skeletal muscle and skin. Muscle Nerve 1997;20:625-7.
42. Rubio A, Rifkin D, Powers JM, Patel U, Stewart J, Faust P et al. Phenotypic variability of CADASIL and novel morphologic findings. Acta Neuropathol 1997;94:247-54.
43. Schultz A, Santoianni R, Hewan-Lowe K. Vasculopathic changes of CADASIL can be focal in skin biopsies. Ultrastruct Pathol 1999;23:241-7.
44. Joutel A, Favrole P, Labauge P, Chabriat H, Lescoat C, Andreux F et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet 2001;358:2049-51.
45. Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, Battail N et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 2000;105: 597-605.
46. Tournier-Lasserve E, Joutel A, Melki J, Weissenbach J, Lathrop GM, Chabriat H et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nature Genet 1993;3:256-9.
47. Mazzei R, Conforti FL, Lanza PL, Sprovieri T, Lupo MR, Gallo O et al. A novel Notch3 gene mutation not involving a cysteine residue in an Italian family with CADASIL. Neurology 2004;63:561-4.
48. Joutel A, Chabriat H, Vahedi K, Domenga V, Vayssiere C, Ruchoux MM et al. Splice site mutation causing a seven amino acid notch3 in-frame deletion in CADASIL. Neurology 2000;54:1874-5.
49. Dichgans M, Ludwig H, Muller-Hocker J, Messerschmidt A, Gasser T. Small in-frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGF-like repeat domains. Eur J Hum Genet 2000;8:280-5.
50. Dichgans M, Herzog J, Gasser T. NOTCH3 mutation involving three cysteine residues in a family with typical CADASIL. Neurology 2001;57:1714-7.
51. Joutel A, Dodick DD, Parisi JE, Cecillon M, Tournier-Lasserve E, Bousser MG. De novo mutation in the Notch3 gene causing CADASIL. Ann Neurol 2000;47:388-91.
52. Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssière C et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 1997;350:1511-5.
53. Lesnik Oberstein SAJ, Ferrari MD, Bakker E, van Gestel J, Kneppers ALJ, Frants RR et al. Diagnostic Notch3 sequence analysis in CADASIL: three new mutations in Dutch patients. Neurology 1999;52:1913-5.
54. Markus HS, Martin RJ, Simpson MA, Dong YB, Ali N, Crosby AH et al. Diagnostic strategies in CADASIL. Neurology 2002;59: 1134-8.
55. Kotorii S, Takahashi K, Kamimura K, Nishio T, Arima K, Yamada H et al. Mutations of the Notch3 gene in non-caucasian patients with suspected cadasil syndrome. Dement Geriatr Cogn Disord 2001;12:185-93.
56. Dichgans M, Filippi M, Bruning R, Iannucci G, Berchtenbreiter C, Minicucci L et al. Quantitative MRI in CADASIL: correlation with disability and cognitive performance. Neurology 1999;52:1361-7.
57. Egan SE, St-Pierre B, Leow CC. Notch receptors, partners and regulators: from conserved domains to powerful functions. Curr Top Microbiol Immunol 1998;228:273-324.
58. Artavanis-Tsanakos S, Matsuno K, Fortini ME. Notch signaling. Science 1995;268:225-32.
59. Karlstrom H, Beatus P, Dannaeus K, Chapman G, Lendahl U, Lundkvist J. A CADASIL-mutated Notch 3 receptor exhibits impaired intracellular trafficking and maturation but normal ligand-induced signaling. Proc Natl Acad Sci U S A 2002;99:17119-24.
60. Haritunians T, Boulter J, Hicks C, Buhrman J, DiSibio G, Shawber C et al. CADASIL Notch3 mutant proteins localize to the cell surface and bind ligand. Circ Res 2002;90:506-8.
61. Joutel A, Monet M, Domenga V, Riant F, Tournier-Lasserve E. Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/JK signaling Pathway. Am J Hum Genet 2004;74:338-47.
62. Peters N, Opherk C, Zacherle S, Capell A, Gempel P, Dichgans M. CADASIL-associated Notch3 mutations have differential effects both on ligand binding and ligand-induced Notch3 receptor signaling through RBP-Jk. Exp Cell Res 2004;299:454-64.
63. Fryxell KJ, Soderlund M, Jordan TV. An animal model for the molecular genetics of CADASIL. Stroke 2001;32:6-11.
64. Donahue CP, Kosik KS. Distribution pattern of Notch3 mutations suggests a gain-of-function mechanism for CADASIL. Genomics 2004;83:59-65.
65. Ruchoux MM, Domenga V, Brulin P, Maciazek J, Limol S, Tournier-Lasserve E et al. Transgenic mice expressing mutant Notch3 develop vascular alterations characteristic of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Am J Pathol 2003;162:329-42.
66. Krebs LT, Xue Y, Norton CR, Sundberg JP, Beatus P, Lendahl U et al. Characterization of Notch3-deficient mice: normal embryonic development and absence of genetic interactions with a Notch1 mutation. Genesis 2003;37:139-43.
67. Okeda R, Arima K, Kawai M. Arterial changes in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in relation to pathogenesis of diffuse myelin loss of cerebral white matter: examination of cerebral medullary arteries by reconstruction of serial sections of an autopsy case. Stroke 2002;33:2565-9.
68. Brulin P, Godfraind C, Leteurtre E, Ruchoux MM. Morphometric analysis of ultrastructural vascular changes in CADASIL: analysis of 50 skin biopsy specimens and pathogenic implications. Acta Neuropathol (Berl) 2002;104:241-8.
69. Chabriat H, Bousser MG, Pappata S. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: a positron emission tomography study in two affected family members. Stroke 1995;26:1729-30.
70. Mellies JK, Bäumer T, Müller JA, Tournier-Lasserve E, Chabriat H, Knobloch O et al. SPECT study of a German CADASIL family. Neurology 1998;50:1715-21.
71. Chabriat H, Pappata S, Ostergaard L, Clark CA, Pachot-Clouard M, Vahedi K et al. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke 2000;31:1904-12.
72. van den Boom R, Lesnik Oberstein SAJ, Spilt A, Behloul F, Ferrari MD, Haan J et al. Cerebral hemodynamics and white matter hyperintensities in CADASIL. J Cereb Blood Flow Metab 2003;23: 599-604.
73. Pfefferkorn T, Stuckrad-Barre S, Herzog J, Gasser T, Hamann GF, Dichgans M. Reduced cerebrovascular CO(2) reactivity in CADASIL: a transcranial Doppler sonography study. Stroke 2001;32:17-21.
74. Liebetrau M, Herzog J, Kloss CU, Hamann GF, Dichgans M. Prolonged cerebral transit time in CADASIL: a transcranial ultrasound study. Stroke 2002;33:509-12.
75. Hussain MB, Singhal S, Markus HS, Singer DR. Abnormal vasoconstrictor responses to angiotensin II and noradrenaline in isolated small arteries from patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Stroke 2004;35:853-8.
76. Chabriat H, Pappata S, Poupon C, Clark CA, Vahedi K, Poupon F et al. Clinical severity in CADASIL related to ultrastructural damage in white matter: in vivo study with diffusion tensor MRI. Stroke 1999;30:2637-43.
77. Molko N, Pappata S, Mangin JF, Poupon C, Vahedi K, Jobert A et al. Diffusion tensor imaging study of subcortical gray matter in cadasil. Stroke 2001;32:2049-54.
78. Molko N, Pappata S, Mangin JF, Poupon F, LeBihan D, Bousser MG et al. Monitoring disease progression in CADASIL with diffusion magnetic resonance imaging: a study with whole brain histogram analysis. Stroke 2002;33:2902-8.
79. Iannucci G, Dichgans M, Rovaris M, Bruning R, Gasser T, Giacomotti L et al. Correlations between clinical findings and magnetization transfer imaging metrics of tissue damage in individuals with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke 2001;32:643-8.
80. Auer DP, Schirmer T, Heidenreich JO, Herzog J, Putz B, Dichgans M. Altered white and gray matter metabolism in CADASIL: a proton MR spectroscopy and 1H-MRSI study. Neurology 2001;56:635-42.
81. Dichgans M, Holtmannspotter M, Herzog J, Peters N, Bergmann M, Yousry TA. Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study. Stroke 2002;33:67-71.
82. Wong KS, Chan YL, Liu JY, Gao S, Lam WW. Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages. Neurology 2003;60:511-3.
83. Newton PN, Thai IH, Tip NQ, Short JM, Chierakul W, Rajanuwong A et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002;35:769-72.
84. Vahedi K, Taupin P, Djomby R, El Amrani M, Lutz G, Filipetti V et al. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. J Neurol 2002;249: 206-11.
85. Davous P. CADASIL: a review with proposed diagnostic criteria. Eur J Neurol 1998;5:219-33.
86. Lesnik Oberstein SAJ, van Duinen SG, van den Boom R, Maat-Schieman ML, van Buchem MA, van Houwelingen HC et al. Evaluation of diagnostic NOTCH3 immunostaining in CADASIL. Acta Neuropathol (Berl) 2003;106:107-11.
87. Lesnik Oberstein SAJ. Diagnostic strategies in CADASIL. Neurology 2003;60:2020.